Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gene screen predicts brain tumour prognosis:

This article was originally published in Clinica

Executive Summary

A team of researchers in Massachusetts, US, has developed a classification system of gene expression profiles that could help predict the clinical outcome of the most common type of childhood malignant brain tumour. Diagnosis of the condition, called medulloblastoma, on the basis of morphologic appearance alone is controversial and patient response to therapy is difficult to predict, according to a report published in Nature (January 24). The new DNA microarray gene expression-based system is highly predictive of outcome at the time of tumour diagnosis and may also shed light on why the tumours occur, said the team from the Massachusetts Institute of Technology, based in Cambridge.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel